A Non-Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF-β1 Signaling

被引:0
作者
Liu, Ruxia [1 ]
Zhou, Ting [2 ,3 ]
Li, Xinsheng [2 ]
Zou, Quan [4 ,5 ]
Yu, Jiaojiao [2 ]
Ye, Jingjing [6 ]
Wang, Wenhui [7 ]
Zhou, Yan [8 ]
Sun, Shao-Kai [2 ]
机构
[1] Tianjin Med Univ, Sch Med Technol, Dept Rehabil, Tianjin 300203, Peoples R China
[2] Tianjin Med Univ, Sch Med Imaging, Tianjin 300203, Peoples R China
[3] Shaanxi Prov Peoples Hosp, Dept CT, Xian 710068, Shaanxi, Peoples R China
[4] Tianjin Med Univ, Sch Med Imaging, Tianjin Key Lab Funct Imaging, Tianjin 300203, Peoples R China
[5] Tianjin Med Univ, Dept Radiol, Hosp 2, Tianjin 300211, Peoples R China
[6] Peking Univ, Minist Educ Natl Ctr Trauma Med, Key Lab Trauma Treatment & Neural Regenerat, Trauma Treatment Ctr,Peking Univ Peoples Hosp, Beijing 100044, Peoples R China
[7] Tianjin Med Univ, Dept Neurol, Hosp 2, Tianjin 300211, Peoples R China
[8] Tianjin Third Cent Hosp, Dept Ultrasound, Tianjin 300170, Peoples R China
关键词
melanin; non-metallic nanozyme; pulmonary hypertension; ROS; TGF-beta; 1; signaling; SMOOTH-MUSCLE-CELLS; ARTERIAL-HYPERTENSION; PROLIFERATION; NANOPARTICLES; FIBROBLASTS; PATHWAY; PROTECT; STRESS;
D O I
10.1002/adhm.202401909
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Pulmonary hypertension (PH) is a life-threatening cardiovascular disease with a lack of effective treatment options. Nanozymes, though promising for PH therapy, pose safety risks due to their metallic nature. Here, a non-metallic nanozyme is reported for the treatment of monocrotaline (MCT)-induced PH with a therapeutic mechanism involving the ROS/TGF-beta 1 signaling. The synthesized melanin-polyvinylpyrrolidone-polyethylene glycol (MPP) nanoparticles showcase ultra-small size, excellent water solubility, high biocompatibility, and remarkable antioxidant capacity. The MPP nanoparticles are capable of effectively eliminating ROS in isolated pulmonary artery smooth muscle cells (PASMCs) from PH rats, and significantly reduce PASMC proliferation and migration. In vivo results from a PH model demonstrate that MPP nanoparticles significantly increase pulmonary artery acceleration time, decrease wall thickening and PCNA expression in lung tissues, as evidenced by echocardiograpy, histology and immunoblot analysis. Additionally, MPP nanoparticles treatment improve running capacity, decrease Fulton index, and attenuate right ventricular fibrosis in MCT-PH rats by using treadmill test, picrosirius red, and trichrome Masson staining. Further transcriptomic and biochemical analyses reveal that inhibiting ROS-driven activation of TGF-beta 1 in the PA is the mechanism by which MPP nanoparticles exert their therapeutic effect. This study provides a novel approach for treating PH with non-metallic nanozymes based on a well-understood mechanism. Pulmonary hypertension (PH) is a life-threatening cardiovascular disease with limited treatment options. Nanozymes hold potential for PH treatment, but existing nanozymes are all metallic, raising safety concerns. In this study, a non-metallic nanozyme, melanin-PVP-PEG (MPP) is reported, which effectively alleviates monocrotaline-induced PH, primarily by inhibiting ROS-TGF-beta 1 signaling. image
引用
收藏
页数:14
相关论文
共 53 条
  • [1] Recent Advances in Nanozymes: From Matters to Bioapplications
    Ai, Yongjian
    Hu, Ze-Nan
    Liang, Xiaoping
    Sun, Hong-bin
    Xin, Hongbo
    Liang, Qionglin
    [J]. ADVANCED FUNCTIONAL MATERIALS, 2022, 32 (14)
  • [2] Mitochondrial metabolism, redox signaling, and fusion:: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer
    Archer, Stephen L.
    Gomberg-Maitland, Mardi
    Maitland, Michael L.
    Rich, Stuart
    Garcia, Joe G. N.
    Weir, E. Kenneth
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2008, 294 (02): : H570 - H578
  • [3] Caregiver burden among parents of children with type 1 diabetes: A qualitative scoping review
    Azimi, Tara
    Johnson, Jeff
    Campbell, Sandra M.
    Montesanti, Stephanie
    [J]. HELIYON, 2024, 10 (06)
  • [4] Polydopamine Nanoparticles as Efficient Scavengers for Reactive Oxygen Species in Periodontal Disease
    Bao, Xingfu
    Zhao, Jiahui
    Sun, Jian
    Hu, Min
    Yang, Xiurong
    [J]. ACS NANO, 2018, 12 (09) : 8882 - 8892
  • [5] Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension
    Bellaye, Pierre-Simon
    Yanagihara, Toyoshi
    Granton, Elise
    Sato, Seidai
    Shimbori, Chiko
    Upagupta, Chandak
    Imani, Jewel
    Hambly, Nathan
    Ask, Kjetil
    Gauldie, Jack
    Iglarz, Marc
    Kolb, Martin
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [6] Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies
    Boucetta, Hamza
    Zhang, Lei
    Sosnik, Alejandro
    He, Wei
    [J]. JOURNAL OF CONTROLLED RELEASE, 2024, 365 : 236 - 258
  • [7] Inflammation and Oxidative Stress Induce NGF Secretion by Pulmonary Arterial Cells through a TGF-β1-Dependent Mechanism
    Bouchet, Clement
    Cardouat, Guillaume
    Douard, Matthieu
    Coste, Florence
    Robillard, Paul
    Delcambre, Frederic
    Ducret, Thomas
    Quignard, Jean-Francois
    Vacher, Pierre
    Baudrimont, Isabelle
    Marthan, Roger
    Berger, Patrick
    Guibert, Christelle
    Freund-Michel, Veronique
    [J]. CELLS, 2022, 11 (18)
  • [8] Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension
    Boucly, Athenais
    Savale, Laurent
    Jais, Xavier
    Bauer, Fabrice
    Bergot, Emmanuel
    Bertoletti, Laurent
    Beurnier, Antoine
    Bourdin, Arnaud
    Bouvaist, Helene
    Bulifon, Sophie
    Chabanne, Celine
    Chaouat, Ari
    Cottin, Vincent
    Dauphin, Claire
    Degano, Bruno
    De Groote, Pascal
    Favrolt, Nicolas
    Feng, Yuanchao
    Horeau-Langlard, Delphine
    Jevnikar, Mitja
    Jutant, Etienne-Marie
    Liang, Zhiying
    Magro, Pascal
    Mauran, Pierre
    Moceri, Pamela
    Mornex, Jean-Francois
    Palat, Sylvain
    Parent, Florence
    Picard, Francois
    Pichon, Jeremie
    Poubeau, Patrice
    Prevot, Gregoire
    Renard, Sebastien
    Reynaud-Gaubert, Martine
    Riou, Marianne
    Roblot, Pascal
    Sanchez, Olivier
    Seferian, Andrei
    Tromeur, Cecile
    Weatherald, Jason
    Simonneau, Gerald
    Montani, David
    Humbert, Marc
    Sitbon, Olivier
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 204 (07) : 842 - 854
  • [9] MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-β1 and IL-6/STAT3 signaling pathways
    Cai, Zongye
    Li, Jian
    Zhuang, Qi
    Zhang, Xueming
    Yuan, Ancai
    Shen, Lan
    Kang, Kang
    Qu, Bo
    Tang, Yuanjia
    Pu, Jun
    Gou, Deming
    Shen, Jieyan
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 : 1 - 11
  • [10] Biomedicine meets nanozyme catalytic chemistry
    Cao, Changyu
    Yang, Nan
    Wang, Xiaorui
    Shao, Jinjun
    Song, Xuejiao
    Liang, Chen
    Wang, Wenjun
    Dong, Xiaochen
    [J]. COORDINATION CHEMISTRY REVIEWS, 2023, 491